Biological: narsoplimab
Phase 2Monoclonal antibody
Biological: narsoplimab is one of 9 small molecule programs targeting Hematopoietic Stem Cell Transplant. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Hematopoietic Stem Cell Transplant
#DrugCompanyPhaseTrials
1Jakafi
IncytePhase 2
Granulocyte Colony-Stimulating Factor
SanofiPhase 2
Clolar
GGenzyme, a Sanofi Company
Preclinical
Cyclosporine a
NovartisPreclinical
Biological: narsoplimab
OOmeros Corporation
Phase 2
Stem Cell Mobilization Therapy
EEastern Cooperative Oncology Group
Phase 2
Campath 1h
Mario Negri Institute for Pharmacological ResearchPreclinical
Reduced Intensity Allogeneic HCT
MMasonic Cancer Center, University of Minnesota
Preclinical
Myeloablative Busulfan
MMasonic Cancer Center, University of Minnesota
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Biological: narsoplimab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 2[1]
- Company
- OOmeros Corporation